Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Teva Pharmaceutical Industries Ltd. (TEVA) had Revenue of $3.89B for the most recently reported fiscal quarter, ending 2025-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-03-31

Income Statement Financials
Revenue	$3.89B
Net Income	$214.00M
Cost of Goods Sold	$2.01B
Gross Profit	$1.88B
Operating Expenses	$3.37B
Operating Income	$521.00M
Non-Operating Income/Expense	$-225.00M
Pre-Tax Income	$294.00M
Normalized Pre-Tax Income	$294.00M
Income after Taxes	$220.00M
Income from Continuous Operations	$220.00M
Consolidated Net Income/Loss	$220.00M
Normalized Income after Taxes	$220.00M
EBIT	$521.00M
EBITDA	$765.00M
Weighted-Average Shares Outstanding (Basic)	1.14B
Weighted-Average Shares Outstanding (Diluted)	1.16B
Earnings per Share (EPS) (Basic)	$0.19
Earnings per Share (EPS) (Diluted)	$0.18
Balance Sheet Financials
Current Assets	$11.53B
Property, Plant, and Equipment	$4.63B
Long-Term Assets	$26.89B
Total Assets	$38.41B
Current Liabilities	$11.16B
Long-Term Debt	$16.23B
Long-Term Liabilities	$20.99B
Total Liabilities	$32.15B
Common Equity	$6.27B
Tangible Shareholders Equity	$-13.40B
Shareholders Equity	$6.27B
Common Shares Outstanding	1.15B
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-105.00M
Cash Flow from Investing Activities	$201.00M
Cash Flow from Financial Activities	$-1.74B
Beginning Cash	$3.30B
End Cash	$1.70B
Increase/Decrease in Cash	$-1.60B
Stock-Based Compensation	$34.00M
Common Stock Dividends Paid	$-340.00M
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.03
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.72
Debt to Equity Ratio	2.66
Gross Margin	48.24%
Operating Margin	13.39%
EBIT Margin	13.39%
EBITDA Margin	--
Pre-Tax Profit Margin	7.56%
Profit Margin	5.50%
Free Cash Flow	$-232.00M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.10
Inventory Turnover	0.62
Receiveable Turnover	1.15
Days Sales in Receivables	78.27
Return on Equity	3.51%
Return on Tangible Equity	-1.64%
Return on Assets	0.57%
Return on Investments	0.98%
Book Value Per Share	$5.47
Free Cash Flow per Share	$-0.20
Operating Cash Flow per Share	$-0.09

Data from Zacks Investment Research, Inc.